European Medicines Agency approves ixekizumab for the treatment of adults with active axial spondyloarthritis

The approval of this anti-IL-17 monoclonal antibody, based on data from 3 placebo-controlled RCTs, covers its use in the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis, where there has been inadequate response to conventional therapies.